ASCO 2016 CLL Research Update

Published on

Topics include: Treatment

What developing research released at ASCO this year should CLL patients know about?  CLL expert Dr. Jeff Sharman joins Patient Power to share his insight into the various changes in the CLL landscape over the past several months and why these changes should encourage patients. Dr. Sharman cites improved outcomes, increased therapeutic tolerance, and longer survival rates with increased quality of life as particular highlights. 

View more programs featuring and

Produced in association with

Related Programs

Personalized Care and CLL

Andrew Schorr and Dr. Nicole Lamanna discuss the ever-changing landscape of CLL and the new role of patients and doctors in this era of personalized medicine.


The Evolving CLL Treatment Landscape

Andrew Schorr interviews CLL expert Dr. Richard Furman to discuss the evolving CLL treatment landscape, including the introduction of venetoclax (Venclexta) to the CLL armamentarium.


What Could a New CLL Drug Approval Mean for Patients?

Dr. William Wierda, medical director of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, joins Patient Power to discuss the approval of Venclexta (venetoclax) for use in CLL patients with the 17p deletion.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on October 4, 2016